Junshi Biosciences, Coherus Receive FDA Breakthrough Therapy Status For Toripalimab In Head & Neck Cancer
- The FDA has granted Breakthrough Therapy Designation (BTD) to Shanghai Junshi Biosciences Co Ltd - Coherus BioSciences Inc's (NASDAQ: CHRS) toripalimab for recurrent or metastatic nasopharyngeal carcinoma (NPC).
- NPC is a rare tumor of the head and neck.
- The designation covers toripalimab combined with chemotherapy (gemcitabine and cisplatin) for the 1st line treatment of NPC.
- The FDA had earlier granted BTD for toripalimab monotherapy for patients with recurrent or metastatic NPC with disease progression on or after platinum-containing chemotherapy.
- Price Action: CHRS shares are up 7.04% at $14.30 during the premarket session on the last check Thursday.
- Related content: Benzinga's Full FDA Calendar.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Biotech Long Ideas News Health Care Small Cap FDA Movers Trading Ideas
